Optical breast imaging technology developer DOBI Medical International yesterday announced a new strategy designed to increase the company's presence in Asia.
The Mahwah, NJ, company signed an agreement with the China Center for Pharmaceutical International Exchange, in which CCPIE will work with DOBI to gain regulatory approval for its ComfortScan system through the Chinese State Food and Drug Administration (SFDA). A clinical study has already begun at two sites in Beijing, where data will be collected in support of a regulatory submission.
In addition, John Zhang has been hired as area business manager, Asia/Pacific to oversee DOBI's activities in the region. Zhang is a native of China and previously was with Boston Instruments before joining DOBI.
Finally, DOBI has retained legal counsel in China, hiring Fong & Ng, one of the area's largest law firms, according to the company.
DOBI considers China a significant potential market for its technology, with more than 300 million women at risk for breast cancer. The death rate for breast cancer has been increasing 3% annually in the country in recent years, and diagnosis of breast cancer has increased by at least 27%.
By AuntMinnie.com staff writers
October 25, 2005
Related Reading
DOBI inks research deal with Dartmouth, October 13, 2005
DOBI teams up with Bio-Imaging, June 9, 2005
DOBI to add trial sites, June 1, 2005
DOBI posts Q1 numbers, May 10, 2005
DOBI signs new distributor in Europe, April 18, 2005
Copyright © 2005 AuntMinnie.com
